Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double-Blind, Placebo-Controlled, Single Oral Dose Study in Healthy Volunteers. J Clin Pharmacol 2008;48:418-27.

Excerpt link:

This double-blind, randomized, placebo-controlled study in health subjects investigated the safety, pharmacokinetics, and pharmacodynamics of single doses of taranabant, a cannabinoid CB-1 receptor inverse agonist in clinical development to treat obesity.